Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for antiplatelet agents Aspirin and extended-release Dipyridamole capsules. The approved product is a generic version of Aggrenox capsules of Boehringer Ingelheim Pharmaceuticals Inc. Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Aspirin and extended-release Dipyridamole capsules in the strength of 25 mg/200 mg, the company said in a BSE filing. Citing IQVIA sales data, Glenmark said, the Aggrenox capsules, 25 mg/200 mg market achieved annual sales of approximately USD 165.6 million in the 12-month period ended March 2019. The company said its current portfolio consists of 155 products authorised for distribution in the US and 58 Abbreviated New Drug Application (ANDA's) pending approval with the USFDA. Shares of Glenmark Pharma were trading 0.03 per cent higher at Rs 559.20 apiece on the BSE.
from Latest News http://bit.ly/2QpFbOl
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P
Home
Business
Business News
Business Standard
Latest News
Glenmark Pharma receives final approval from USFDA for antiplatelet drug
Monday, May 27, 2019
Related Posts:
Brexit report to consider workforce impactMore than 400 businesses and industry bodies contributed to the Migrat… Read More
Ex-UBS trader gets last-minute reprieve from deportationA judge has awarded a judicial review of the case of the former UBS tr… Read More
Anger mounts over House of Fraser gift cardsThe store's new owners told customers to send in gift cards, but a mon… Read More
'I dialled into work and prayed my baby wouldn't wake up'Winning flexible working hours can bring a new set of major problems, … Read More
0 comments: